BIAT - Innovation and High Technology Lab, funded under the Cohesion Action Plan of Italy’s Economic Development Ministry, is an initiative designed to support Southern Italian startups to find partners and investors abroad. The event is organised by the Italian Trade Commission - ITA in collaboration with key Regional Governments: Abruzzo, Molise, Sardinia, Basilicata, Campania, Calabria, Apulia and Sicily. The focus sectors include medical, health and biotechnology, green economy (circular economy, renewable energy, environment), ICT, aerospace, innovative materials, nanotechnologies

An Italian life sciences company is planning to establish its new U.S. hub in central Indiana. Stevanato Group says it will invest up to $145 million to build and equip a 370,000-square-foot manufacturing facility in Fishers and create more than 230 jobs by the end of 2025. The company, which provides drug containment, drug delivery and diagnostic services for the pharmaceutical, biotechnology and life sciences industries, says the facility will support the expansion and production of its EZ-Fill solutions. Construction on the plant is expected to begin later this year. Stevanato Group says

BIAT - Innovation and High Technology Lab, funded under the Cohesion Action Plan of Italy’s Economic Development Ministry, is an initiative designed to enable enterprises and research systems of southern Italy in particular, the regions of Abruzzo, Molise, Sardinia, Basilicata, Campania, Calabria, Apulia and Sicily - to express their full potential for innovation and excellence. The event is organised by the Italian Trade Agency in collaboration with the partnering Regional Governments. BIAT aims to promote the placing on the market and/or the transfer of innovative products and services or

THE BIOTECH SECTOR IN ITALY: A GROWING AND PROMISING REALITY Vigorous growth and an excellent innovation capacity. These are the principal characteristics of the Italian biotech sector. In view of the tender age of this industry such characteristics are, in some respects, very surprising. Thanks to them, Italy has managed to meet a challenge that would have been unthinkable a few years ago: to finally appear on the radar screens of the major biopharmaceutical and biotechnological companies and venture capital operators. There are tangible facts behind this phenomenon: new enterprises emerging